Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial
Osamu Aramaki(Nihon University), Masashi Fujii(Nihon University), Hidemori Sakamoto(University of Miyazaki Hospital), Norihiro Kokudo(National Center for Global Health and Medicine), Hiraku Yodono, Seiji Kawasaki(Mitsui Memorial Hospital), Naoki Yamanaka(Miwa Hospital), Eigo Otsuji(Kyoto Prefectural University of Medicine), Shinji Tanaka(Tokyo Institute of Technology), Yo Sasaki(SHOWA Medical University), Keiichi Kubota(Southern Tohoku General Hospital), Tadatoshi Takayama(Nihon University), Yutaka Matsuyama(The University of Tokyo), Masamichi Moriguchi(Nihon University)
Cited by 24
Related Papers
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
|Science|2004|1.1k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice
|Cell Metabolism|2016|900
Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
|Cell Metabolism|2007|899
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780